Perhaps Coppashaft has additional information, but from what is published by the FDA about the upcoming meetings he referenced, Avita's ReCell does not seem to be on the agenda for either the 17th or 18th Oct. meetings. Two other company's drugs are listed for discussion, not ReCell.
For the rest of the year, here is a thumbnail sketch of the upcoming topics of the public meetings.
October
October 3 - Science Board to the FDA
October 15-16 – Gastrointestinal Drugs Advisory Committee
October 17-18 – Endocrinologic and Metabolic Drugs Advisory Committee
October 23-24 - Science Advisory Board to the National Center for Toxicological Research
October 24 - Radiological Devices Panel of the Medical Devices Advisory Committee
October 29-30 – Drug Safety and Risk Management Advisory Committee
November
November 1 - Neurological Devices Panel of the Medical Devices Advisory Committee
November 1-2 - Risk Communication Advisory Committee
November 2 - Anti-Infective Drugs Advisory Committee
November 6-7 - Oncologic Drugs Advisory Committee
November 7-8 – Endocrinologic and Metabolic Drugs Advisory Committee
November 7-8 -Technical Electronic Product Radiation Safety Standards Committee
November 9 - Nonprescription Drugs Advisory Committee
November 14 - Circulatory System Devices Panel of the Medical Devices Advisory Committee
November 14-15 - Vaccines and Related Biological Products Advisory Committee
November 28-29 - Anti-Infective Drugs Advisory Committee
November 29 - Cellular, Tissue and Gene Therapies Advisory Committee
December
December 4-5 - Blood Products Advisory Committee
December 4-5 - Oncologic Drugs Advisory Committee
December 5-6 - Circulatory System Devices Panel of the Medical Devices Advisory Committee
December 6-7 - Orthopedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee
December 7 - Anesthetic and Analgesic Drug Products Advisory Committee
December 12-13 – Drug Safety and Risk Management Advisory Committee
December 13-14 - Food Advisory Committee
- Forums
- ASX - By Stock
- avita not on the fda 17/18 oct agenda
Perhaps Coppashaft has additional information, but from what is...
Featured News
Add AVH (ASX) to my watchlist
(20min delay)
|
|||||
Last
$3.84 |
Change
-0.120(3.03%) |
Mkt cap ! $268.3M |
Open | High | Low | Value | Volume |
$3.94 | $3.94 | $3.76 | $511.0K | 134.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | $3.77 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$3.84 | 11883 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 3.770 |
1 | 266 | 3.750 |
1 | 400 | 3.720 |
2 | 3270 | 3.700 |
4 | 2671 | 3.650 |
Price($) | Vol. | No. |
---|---|---|
3.840 | 11883 | 1 |
3.850 | 5926 | 1 |
3.860 | 9868 | 1 |
3.880 | 1102 | 2 |
3.900 | 4769 | 2 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
AVH (ASX) Chart |
The Watchlist
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online